References
- Gressler LE, Hammond DA, Painter JT. Serotonin syndrome in tapentadol literature: systematic review of original research. J Pain Palliat Care Pharmacother. 2017;31(3-4):228–236.
- Tzschentke TM, Christoph T, Kögel B, Schiene K, Hennies HH, Englberger W, Haurand M, Jahnel U, Cremers TIFH, Friderichs E, et al. (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): anovel l-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Expert Ther. 2007;323:265–276.
- Schröder W, De Vry J, Tzschentke TM, Jahnel U, Christoph T. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Eur J Pain. 2010:814–821.
- Tzschentke TM, Christoph T, Kögel BY. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol. CNS Drugs. 2014;28:319–329.
- Baron R, Eberhart L, Kern KU, Regner S, Rolke R, Simanski C, Tölle T. Tapentadol prolonged release for chronic pain: a review of clinical trials and 5 years of routine clinical practice data. Pain Pract. 2017; 17:678–700.
- Electronic Medicines Compendium. Palexia SR prolonged release tablets. Summary of product characteristics. Last Updated on Jan 03, 2018. https://www.medicines.org.uk/emc/medicine/28373. Accessed Feb 7, 2018.
- Brett V, Sikes C, Xiang J, Oh C, Biondi D. Post hoc analysis of pooled safety data from eleven phase 3 clinical trials to identify potential pharmacodynamic drug interactions between tapentadol and SSRIs/SNRIs. J Pharm Pract. 2012;25:265.
- Schmidt P. Safety information on serotonin syndrome for tapentadol IR and tapentadol ER administration (Abstract poster 212). http://www.painmed.org/2016posters/abstract-212/Accessed Feb 7, 2018.
- Vorsanger G, Biondi D, Sorra K, Brett V, Quach P, Xiang J, Koch D, Stegmann JU, Häufel T. Post hoc analyses of data from phase 3 clinical trials of immediate-release tapentadol suggest no evidence of the serotonin syndrome. J Clin Pharmacol. 2009;49(9):1101 (abstract 50).
- Stollenwerk A, Sohns M, Heisig F, Elling C, von Zabern D. Review of post-marketing safety data on tapentadol, a centrally acting analgesic. Adv Ther. 2018;35:12–30.